Oncotarget

Research Papers:

Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy

Hima Bindu Ruttala, Thiruganesh Ramasamy, Bijay Kumar Poudal, Yongjoo Choi, Ju Yeon Choi, Jeonghwan Kim, Sae Kwang Ku, Han-Gon Choi, Chul Soon Yong and Jong Oh Kim _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:14925-14940. https://doi.org/10.18632/oncotarget.14742

Metrics: PDF 2188 views  |   HTML 5673 views  |   ?  


Abstract

Hima Bindu Ruttala1, Thiruganesh Ramasamy1, Bijay Kumar Poudal1, Yongjoo Choi1, Ju Yeon Choi1, Jeonghwan Kim1, Sae Kwang Ku2, Han-Gon Choi3, Chul Soon Yong1, Jong Oh Kim1

1College of Pharmacy, Yeungnam University, 214-1, Dae-dong, Gyeongsan, 712-749, South Korea

2College of Korean Medicine, Daegu Haany University, Gyeongsan, 712-715, South Korea

3College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Sangnok-gu, Ansan 426-791, South Korea

Correspondence to:

Jong Oh Kim, email: [email protected]

Chul Soon Yong, email: [email protected]

Keywords: paclitaxel, histone deacetylase inhibitor, albumin, transferrin, lipid bilayer

Received: October 17, 2016     Accepted: January 10, 2017     Published: January 19, 2017

ABSTRACT

In this study, a transferrin-anchored albumin nanoplatform with PEGylated lipid bilayers (Tf-L-APVN) was developed for the targeted co-delivery of paclitaxel and vorinostat in solid tumors. Tf-L-APVN exhibited a sequential and controlled release profile of paclitaxel and vorinostat, with an accelerated release pattern at acidic pH. At cellular levels, Tf-L-APVN significantly enhanced the synergistic effects of paclitaxel and vorinostat on the proliferation of MCF-7, MDA-MB-231, and HepG2 cancer cells. Vorinostat could significantly enhance the cytotoxic potential of paclitaxel, induce marked cell apoptosis, alter cell cycle patterns, and inhibit the migratory capacity of cancer cells. In addition, Tf-L-APVN showed prolonged circulation in the blood and maintained an effective ratio of 1:1 (for paclitaxel and vorinostat) throughout the study period. In HepG2 tumor-bearing mice, Tf-L-APVN displayed excellent antitumor efficacy and the combination of paclitaxel and vorinostat significantly inhibited the tumor growth. Taken together, dual drug-loaded Tf receptor-targeted nanomedicine holds great potential in chemotherapy of solid tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14742